JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
3201 (feline lymphoid) cells, 81C (sarcoma-positive, leukemia-negative feline lung fibroblast) cells, and primary feline bone marrow cells
Reaction Conditions
0 ~ 384 μM zalcitabine
Applications
Zalcitabine (5 ~ 10 μM) inhibited feline leukemia virus (FeLV) infection of feline lymphoid cells by greater than 80%, while 6.07 ~ 12.13 μM zalcitabine was required to similarly inhibit infection of feline fibroblasts. However, 43 ~ 384 μM zalcitabine was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%.
Animal models
Cats challenged intravenously with FeLV 1 ~ 3 days after drug treatment began
Dosage form
22, 15, 10, and 5 mg/kg per h
Administered by continuous intravenous infusion for 28 days
Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The 10 mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 or 5 mg of zalcitabine per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 ~ 7 weeks in seven of nine remaining animals.
Note
The technical data provided above is for reference only.
References:
1. Polas PJ, Swenson CL, Sams R, et al. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrobial Agents and Chemotherapy, 1990, 34(7): 1414-1421.
